Waitemata DHB are seeking a 0.5FTE Skin Cancer Specialist to work with the Cutaneous Oncology Service to see and treat skin cancer patients referred to Waitemata DHB.
The Australian College of Dermatologists (ACD) has released a new guideline for sentinel node biopsy.
This study proposes integrated diagnostic networks which could be used to support and aid dermatologists for further improvement in skin cancer diagnosis.
This recent study identifies sphingosine kinase-1 (SK1) as a key regulator of anti-tumor immunity, and concludes that targeting this checkpoint lipid kinase could enhance immunotherapy.
The American Joint Committee on Cancer (AJCC) maintains that the eighth edition of its Staging Manual (AJCC8) has improved accuracy compared to the seventh (AJCC7). According to this recent study, AJCC8 enables more accurate prognosis for patients with stage III melanoma. Restaging a large cohort of patients can enhance the analysis of active clinical trials.
Uveal melanoma is a highly metastatic cancer that, in contrast to cutaneous melanoma, is largely unresponsive to checkpoint immunotherapy. This recent single-cell analysis study identified the checkpoint marker LAG3 as a potential candidate for immune checkpoint blockade in patients with high risk uveal melanoma.
According to this recent study, patients with primary cutaneous malignant melanoma (MM) are at increased risk for primary noncutaneous MM as well as noncutaneous second primary malignancies (SPMs) that include numerous tumor types. Enhanced oncologic surveillance for a variety of tumor types in melanoma survivors is warranted.
This recent study assessed the performance of S100B in detecting early disease progression in high‐risk melanoma patients. It concludes that rising serum S100B values within the normal range can be an important clue to disease progression.
According to this recent study, FUT4 is a novel biomarker and regulator of the migration and invasion of melanoma cells and may serve as a therapeutic target for melanoma.
According to this recent review, targeted therapies effective in the treatment of cutaneous melanoma and mucosal melanomas may be effective in the treatment of patients with metastatic conjunctival melanoma. The study concludes that conjunctival melanoma patients should be included in major trials studying new therapies in both cutaneous and mucosal melanomas.